The Defiance Daily Target 2X Long LMND ETF (NASDAQ: LMNX) seeks daily investment results, before fees and expenses, of 200% (2x long) of the daily performance of Lemonade Inc. The fund is an actively managed exchange-traded fund designed to deliver twice the daily percentage gain of LMND’s stock price.

Lemonade Inc. is a digital insurance company that leverages artificial intelligence and behavioral economics to provide renters, homeowners, pet, and life insurance products. The company differentiates itself through a fully digital platform, rapid claims processing, and a flat-fee business model. While Lemonade operates in the large and growing insurance market, it is also characterized by high growth expectations, ongoing profitability challenges, and sensitivity to interest rates and underwriting performance.

Traders looking to capitalize on short-term upward movements in LMND shares can use the Defiance Daily Target 2X Long LMND ETF as a leveraged tool to express a bullish view.

The ETF has a focused and leveraged objective:
• To seek daily investment results, before fees and expenses, corresponding to two times (2x) the daily performance of Lemonade Inc.

This ETF is not intended for long-term investors. It is a specialized, high-risk instrument designed for experienced traders who understand leverage and actively manage positions.

Intended Uses

1. Leveraged Bullish Exposure:
   Traders with short-term conviction that LMND stock will rise—due to improving loss ratios, strong earnings, user growth, or favorable macro trends—may use this ETF to amplify potential gains on upward moves.
2. Event-Driven Trading:
   The ETF can be used around key catalysts such as Lemonade earnings releases, product launches, or macroeconomic developments (e.g., interest rate changes) that could trigger sharp upward movements in the stock.
3. Tactical Portfolio Allocation:
   Active traders may use LMNX to temporarily increase exposure to Lemonade without directly purchasing shares, allowing for leveraged participation in short-term price trends.

Key Considerations and Risks

• Compounding Risk: LMNX resets leverage daily. Over periods longer than one trading day, performance may differ significantly from 2x the cumulative return of LMND stock, especially in volatile conditions.
• High Volatility: Lemonade is a high-growth, tech-driven insurance company. Its stock can experience large price swings, which are amplified in a 2x leveraged ETF, increasing both potential gains and losses.
• Company-Specific Risk: Factors such as underwriting performance, claims ratios, customer growth, regulatory developments, and path to profitability can materially impact returns.
• Market and Sector Sensitivity: LMND is influenced by broader insurtech, fintech, and technology sector trends, as well as macroeconomic factors like interest rates and inflation.
• Higher Costs: Leveraged ETFs typically carry higher expense ratios than traditional ETFs, which can erode returns if held for extended periods.

Technical Price Chart

Conclusion

The Defiance Daily Target 2X Long LMND ETF (LMNX) is a tactical trading instrument for investors seeking to capitalize on short-term bullish movements in Lemonade Inc. By offering 2x daily leveraged exposure, it allows traders to amplify gains when LMND stock rises.

However, due to daily leverage resets, amplified volatility, and company-specific risks tied to a high-growth insurtech business model, LMNX carries significant risk. It requires active monitoring, disciplined execution, and a clear short-term strategy, making it more suitable for experienced traders rather than long-term investors.

Note 1: Past performance is not a reliable indicator of future performance.
Note 2: Reference data for price, technical indicators, support, and resistance levels is as of April 14 , 2026 and partly sourced from REFINITIV.
Note 3: Investment decisions should consider an individual’s risk appetite, upside potential, holding period, and prior holdings.
Note 4: Kalkine reports are based on prices captured from NASDAQ, NYSE, and/or REFINITIV, which may have a 15-20 minute lag. Future results may not be consistent with this report, and information is subject to change without notice.